Skip to main content
. 2023 Oct 6;30(4):824–835. doi: 10.1158/1078-0432.CCR-23-1689

Figure 3.

Figure 3. Kaplan–Meier analysis of OS by PD-L1 subgroup in durvalumab plus tremelimumab plus EP arm (A), durvalumab plus EP arm (B), and EP arm (C). CI, confidence interval; EP, platinum-etoposide; HR, hazard ratio; IC, immune cell; OS, overall survival; PD-L1, programmed cell death ligand-1; TC, tumor cell.

Kaplan–Meier analysis of OS by PD-L1 subgroup in durvalumab plus EP arm (A), durvalumab plus tremelimumab plus EP arm (B), and EP arm (C). CI, confidence interval; EP, platinum-etoposide; HR, hazard ratio; IC, immune cell; OS, overall survival; PD-L1, programmed cell death ligand-1; TC, tumor cell.